Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab open-label extension study in thyroid eye disease
2017-002713-58Phase 3Completed
- Sponsor
- Horizon Therapeutics
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of teprotumumab in Graves Orbitopathy (GO) and Graves' ophthalmopathy (TED), sponsored by Horizon Therapeutics. Primary endpoint: Proptosis responder rate at Week 24. Started May 2018; status: completed.
02
Drugs
teprotumumab
03
Conditions
Graves Orbitopathy (GO)Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on 2017-002713-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002713-58.